Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

WCM/EADO 2021 | CMP-001 for PD-1 refractory patients with melanoma

Art Krieg, MD, Checkmate Pharmaceuticals, Cambridge, MA, outlines the potential of CMP-001 as an alternative therapy for patients who do not respond to PD-1 targeted checkpoint inhibitor therapy. CMP-001 is a virus-like particle that is a CpGA DNA toll-like receptor 9 agonist which triggers a strong T-cell response. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

Disclosures

Art Krieg, MD, is the Founder and CSO of Checkmate Pharmaceuticals.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.